ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Xiaoqi Li Li
Matched on ORCID iD 0000-0003-1443-0151; OpenAlex author ID A5100634704. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 5
- Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
- Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44321-024-00060-y↗
- Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
- Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Co-author DOI 10.1016/j.semcancer.2022.03.021↗
- Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Co-author DOI 10.1016/j.semcancer.2022.08.009↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Surinder K. Batra · 4 shared papers, 2022–2025 · strength 0.72
- Paper Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-pa… DOI 10.1038/s41698-025-01046-w↗
- Paper Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. DOI 10.1016/j.semcancer.2022.03.021↗
- Paper Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. DOI 10.1016/j.semcancer.2022.08.009↗
- Maneesh Jain · 3 shared papers, 2022–2025 · strength 0.54
- Paper Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-pa… DOI 10.1038/s41698-025-01046-w↗
- Paper Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. DOI 10.1016/j.semcancer.2022.08.009↗
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Sushil Kumar K · 3 shared papers, 2022–2023 · strength 0.51
- Paper Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. DOI 10.1016/j.semcancer.2022.03.021↗
- Paper Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. DOI 10.1016/j.semcancer.2022.08.009↗
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Namita Bhyravbhatla · 2 shared papers, 2022–2025 · strength 0.40
- Rakesh Bhatia · 2 shared papers, 2022–2023 · strength 0.34
- Hareesh B Nair · 1 shared paper, 2025 · strength 0.21
- Parthasarathy Seshacharyulu · 1 shared paper, 2025 · strength 0.21
- Sushil Kumar · 1 shared paper, 2025 · strength 0.21
- Shailendra Kumar Gautam · 1 shared paper, 2025 · strength 0.21
- Zahraa Wajih Alsafwani · 1 shared paper, 2025 · strength 0.21
- Rick Bhatia · 1 shared paper, 2025 · strength 0.21
- Mokenge Peter Malafa · 1 shared paper, 2025 · strength 0.21
- Moorthy Palanimuthu Ponnusamy · 1 shared paper, 2025 · strength 0.21
- Alaina C. Larson · 1 shared paper, 2022 · strength 0.17
- Joyce C. Solheim · 1 shared paper, 2022 · strength 0.17
- Simin Wang · 1 shared paper, 2024 · strength 0.16
- Liwei Wang · 1 shared paper, 2024 · strength 0.16
- Jiujie Cui · 1 shared paper, 2024 · strength 0.16
- Yuexiang Wang · 1 shared paper, 2024 · strength 0.16
- Andrew C. Cannon · 1 shared paper, 2023 · strength 0.15
- Koelina Ganguly · 1 shared paper, 2023 · strength 0.15
- Naveenkumar Perumal · 1 shared paper, 2023 · strength 0.15
- Jesse L. Cox · 1 shared paper, 2023 · strength 0.15
- Christopher M. Thompson · 1 shared paper, 2023 · strength 0.15
- Satyanarayana Rachagani · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.